Global Blood Urea Nitrogen Diagnostics Market Overview
The Global Blood Urea Nitrogen Diagnostics Market size is expected to grow from USD 1.88 billion in 2023 to USD 3.19 billion by 2032, at a CAGR of 6.04 % during the forecast period (2024-2032).
- A blood urea nitrogen (BUN) test assesses the concentration of urea nitrogen in the bloodstream. Urea nitrogen is a byproduct resulting from the breakdown of proteins in the diet, synthesized in the liver, and transported through the blood to the kidneys for filtration and elimination. This test is frequently included in a comprehensive metabolic panel, a set of diagnostic tests. Its primary purpose is to aid in the detection and monitoring of kidney diseases or disorders.
- By measuring the BUN levels, healthcare providers can gather valuable insights into kidney function. Elevated BUN levels may indicate conditions such as acute or chronic kidney disease, dehydration, or heart failure, where kidneys may not effectively filter waste from the blood. Conversely, abnormally low BUN levels could suggest liver disease or malnutrition.
- During the BUN test, a blood sample is typically drawn from a vein in the arm. Results are interpreted alongside other tests to provide a comprehensive view of metabolic health. Monitoring BUN levels over time helps healthcare professionals assess kidney function stability or progression of kidney-related conditions, guiding treatment decisions and adjustments in patient care.
- In addition to its role in diagnosing and monitoring kidney function, the BUN test also serves as an indicator of overall health and hydration status. Since urea nitrogen is produced from protein breakdown and cleared by the kidneys, abnormal BUN levels can reflect issues beyond kidney function alone.
Market Dynamics And Factors For Blood Urea Nitrogen Diagnostics Market
Drivers:
Growing Renal Failure Patients Around the World
In the last few decades increasing the number of kidney failure and kidney disease patients is the major factor that drives the growth of the blood urea nitrogen diagnostic market. Kidney disease includes Fabry disease, cystinosis, glomerulonephritis, IgA nephropathy, lupus nephritis, atypical hemolytic uremic syndrome, and polycystic kidney disease. The blood urea nitrogen diagnostic test is prescribed when any kidney disease suspect in people. This test helps to understand if there is any need to carry out dialysis or not. Owing to rising noncommunicable diseases, changing lifestyles, and habits, growing aging population the cases of kidney-diseased patients increased. For instance, about 200,000-350,000 people are affected per year by IgA nephropathy is a common form of primary glomerulonephritis. In the year 2020, 431,288 people were diagnosed with kidney cancer in the world. Diabetes is the leading cause of chronic kidney diseases. In recent years, the prevalence of diabetes is increased. The following figure shows the number of diabetics in the world.
Thus, the growing number of kidney disease patients supports the growth of the blood urea nitrogen diagnostics market.
Restraints:
High Cost for the Diagnosis Test
The cost associated with the testing equipment is high is the key factor responsible for restricting the market growth. The prices of the kits, chemical reagents, and other instruments required for the blood urea nitrogen diagnostic test are high. Moreover, to perform the diagnostic test, there is a requirement for extra training for technicians which increases the prices of the diagnostic test. The new advanced techniques used in the laboratory for the detection of blood urea nitrogen also increase the cost of tests which may hamper the growth of the market.
Opportunity:
Opportunity in The Growing FDA Approvals and Launch of New Point-Of-Care Tests
With the rising FDA approvals of the diagnostic test and launching of the novel, point-of-care diagnostics tests will provide a lucrative opportunity for the blood urea nitrogen diagnostics market during the forecast periods. Due to the growing prevalence of renal chronic diseases, the manufacturers of the healthcare sector rising their investment in the research and development of new point-of-care tests for diagnosis. For instance, in 2022 Bloom Diagnostic, a manufacturer of medical devices launched a new kidney test product named bloom kidney test. Additionally, the FDA approvals of such a diagnostic test are also increased. For instance, FDA approved the blood urea nitrogen point-of-care tests of Siemens Healthineers. Thus, the rising R&D of point-of-care tests and FDA approvals offers a profitable opportunity for the market in the analysis period.
Segmentation Analysis Of Blood Urea Nitrogen Diagnostics Market
By Test Type, the ELISA test (Enzyme-linked immunosorbent assay) is expected to account for the largest market share in the forecasted period. ELISA is the most ideal test for the detection of urea nitrogen in the blood and it is commonly used in laboratories. The ELISA test has several benefits such as, it has a simple procedure, high specificity, and sensitivity, and high efficiency and cost-effectiveness. Moreover, this test is safe and eco-friendly because there is no requirement for any radioactive substance and a large number of organic solvents. Additionally, the growing research and development investment in the ELISA kit, the rising geriatric population, and growth in the biopharmaceutical and biotechnology industries increase the market share of the ELISA test in the blood urea nitrogen diagnostics.
By Application, the laboratory segment is predicted to have the maximum market share in blood urea nitrogen diagnostics. The blood urea nitrogen diagnostic test is mostly performed in the laboratory. According to the Centers for disease control and prevention, 70% of the decisions of medical are based on the result of the laboratory and nearly 14 billion laboratory tests are ordered annually. Statista stated that in 2020 there were 331 million laboratory tests conducted in Russia’s public as well as private organizations. Owing to the growing prevalence of various chronic diseases the number of diagnostic laboratories and clinical laboratories is increasing. The test performed in the laboratories is safe, accurate, and cost-effective. Thus, the laboratory has the highest market share in blood urea nitrogen diagnostics.
Regional Analysis Of Blood Urea Nitrogen Diagnostics Market
Asia Pacific region is expected to have the largest market share of the Blood Urea Nitrogen Diagnostics market in the projected period. In this region, the largest population suffers from chronic kidney disease. This is due to the growing prevalence of diabetes. Diabetes is the main cause of chronic kidney disease. For instance, according to Statista, in 2021 there were 206 million people in the western pacific and 90 million people in Southeast Asia suffering from diabetes. China and India in this region have the highest population with the fastest aging population. Chronic kidney diseases mostly affected aged people. In addition to this, geographic, climatic, cultural, social, and environmental diversity in this region is higher than in other regions of the world. The large population in this region experienced the climate-related burden of infectious disease. These infectious diseases are the cause of chronic kidney disease. Thus, in the APAC region, the highest number of kidney failure patients and hence require to test urea nitrogen in the blood which supports the growth of the market of this region.
Europe is the second-dominated region in the blood urea nitrogen diagnostic market. This is owing to the high number of diabetes people suffering from chronic kidney diseases. For instance, according to Statista, there were 61 million people had diabetes in 2021 in the Europe region. Spain had the highest number of kidney transplant population in 2021 and the population was 63.2 per million. Due to economic and environmental changes in this region, the prevalence of infectious diseases is increased. Moreover, the manufacturers in the healthcare sector and also the government increase their investment in the research and development of new diagnostic products. These all factors are expected to increase the blood urea diagnostic market during the forecast periods.
North America has the fastest growth in blood urea nitrogen diagnostics due to growing awareness about the diagnosis of chronic diseases. The changing lifestyle, habits, and environmental changes are susceptible to an increase in the prevalence of infectious diseases which cause chronic kidney disease. For instance, according to the Centers for disease control and prevention report 2021, there were 37 million peoples in the United States have Chronic kidney disease. North American region is financially well developed, thus there is a high investment in the development of new diagnostic products. Due to the growing prevalence of chronic diseases, the government of this region also increases its investments in R&D activities in the healthcare sector. Thus, it is predicted that the market of blood urea nitrogen diagnostics in North America will be increased during the projection period.
Top Key Players Covered In Blood Urea Nitrogen Diagnostics Market
- Siemens AG (Germany)
- StressMarq Biosciences Inc (Columbia)
- Thermo Fisher Scientific (US)
- Xpress Bio Life Science (US)
- PerkinElmer, Inc. (US)
- OPTI Medical Systems, Inc. (USA)
- Abbott Laboratories (US)
- F. Hoffmann-La Roche AG (Switzerland)
- Danaher Corporation (US)
- Bio-Rad Laboratories, Inc. (US)
- Sysmex Corporation (Japan)
- BioVision Inc. (US)
- Randox Laboratories Ltd. (UK)
- HORIBA, Ltd. (Japan)
- Cutera (USA), and other major players.
Key Industry Development In The Blood Urea Nitrogen Diagnostics Market
- In July 2022, the world's leading provider of scientific services, Thermo Fisher Scientific Inc., is presenting cutting-edge diagnostic technologies, assays, and a full range of solutions for researchers creating new diagnostics. Thermo Fisher is exhibiting in booth #1413 at the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), which takes place at the McCormick Place Convention Center in Chicago, July 24-28.
Global Blood Urea Nitrogen Diagnostics Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024 - 2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.88 Bn. |
Forecast Period 2024 - 32CAGR: |
6.04 % |
Market Size in 2032: |
USD 3.19 Bn. |
Segments Covered: |
By Test Type |
|
|
By Application |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Test Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Blood Urea Nitrogen Diagnostics Market by Test Type
5.1 Blood Urea Nitrogen Diagnostics Market Overview Snapshot and Growth Engine
5.2 Blood Urea Nitrogen Diagnostics Market Overview
5.3 ELISA
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 ELISA: Geographic Segmentation
5.4 Colorimetric
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Colorimetric: Geographic Segmentation
5.5 Spectrophotometric
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Spectrophotometric: Geographic Segmentation
Chapter 6: Blood Urea Nitrogen Diagnostics Market by Application
6.1 Blood Urea Nitrogen Diagnostics Market Overview Snapshot and Growth Engine
6.2 Blood Urea Nitrogen Diagnostics Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Laboratory
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Laboratory: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Blood Urea Nitrogen Diagnostics Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Ansoff Matrix
7.1.5 Blood Urea Nitrogen Diagnostics Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Blood Urea Nitrogen Diagnostics Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 SIEMENS AG
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 STRESSMARQ BIOSCIENCES INC.
7.4 THERMO FISHER SCIENTIFIC
7.5 XPRESS BIO LIFE SCIENCE
7.6 PERKINELMER INC.
7.7 OPTI MEDICAL SYSTEMS INC.
7.8 ABBOTT LABORATORIES
7.9 F. HOFFMANN-LA ROCHE AG
7.10 DANAHER CORPORATION
7.11 CUTERA
7.12 OTHER MAJOR PLAYERS
Chapter 8: Global Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Test Type
8.2.1 ELISA
8.2.2 Colorimetric
8.2.3 Spectrophotometric
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Laboratory
Chapter 9: North America Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Test Type
9.4.1 ELISA
9.4.2 Colorimetric
9.4.3 Spectrophotometric
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Laboratory
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Europe Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Test Type
10.4.1 ELISA
10.4.2 Colorimetric
10.4.3 Spectrophotometric
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Laboratory
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
Chapter 11: Asia-Pacific Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Test Type
11.4.1 ELISA
11.4.2 Colorimetric
11.4.3 Spectrophotometric
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Laboratory
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
Chapter 12: Middle East & Africa Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Test Type
12.4.1 ELISA
12.4.2 Colorimetric
12.4.3 Spectrophotometric
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Laboratory
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
Chapter 13: South America Blood Urea Nitrogen Diagnostics Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Test Type
13.4.1 ELISA
13.4.2 Colorimetric
13.4.3 Spectrophotometric
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Laboratory
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
Global Blood Urea Nitrogen Diagnostics Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024 - 2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.88 Bn. |
Forecast Period 2024 - 32CAGR: |
6.04 % |
Market Size in 2032: |
USD 3.19 Bn. |
Segments Covered: |
By Test Type |
|
|
By Application |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Blood Urea Nitrogen Diagnostics Market research report is 2024-2032.
Siemens AG (Germany), StressMarq Biosciences Inc (Columbia), Thermo Fisher Scientific (US), Xpress Bio Life Science (US), PerkinElmer, Inc. (US), OPTI Medical Systems, Inc. (USA), Abbott Laboratories (US), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), Cutera (USA), and other major players.
The Blood Urea Nitrogen Diagnostics Market is segmented into Test Type, Application, and region. By Test Type the market is categorized into ELISA, Colorimetric, and Spectrophotometric. By Application, the market is categorized into Hospital, Laboratory. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.).
Urea nitrogen is the waste product formed in the liver and removed from the blood by the kidneys. The normal level of urea nitrogen in the blood is 6-24mg/dl. If the level of urea nitrogen is increased than normal, it is a sign of the kidneys aren’t working well. The blood urea nitrogen test is referred to as the BUN diagnostic test which is used to measure the urea nitrogen amount in the blood.
The Global Blood Urea Nitrogen Diagnostics Market size is expected to grow from USD 1.88 billion in 2023 to USD 3.19 billion by 2032, at a CAGR of 6.04 % during the forecast period (2024-2032).